Lin BioScience Inc. (6696.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Lin BioScience Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Gross profit | -20.21 m TWD | – |
| Operating income | -1.46 bn TWD | -2.86 bn TWD |
| EBIT | -1.46 bn TWD | -2.64 bn TWD |
| Net income | -744.27 m TWD | -1.36 bn TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. Lin BioScience, Inc. is headquartered in Taipei, Taiwan.
More stocks
- SLM Corp (SLM)
- Endeavour Group Ltd (EDV.AX)
- Zhongfu Shenying Carbon Fiber Co. Ltd. A (688295.SS)
- Longfor Group Holdings Ltd (960.HK)
- XTB SA (XTB.WA)
- Kiwoom (039490.KS)
- Doosan Pref Shs (000155.KS)
- MDU RESOURCES GROUP INC (MDU)
- SUZHOU KEMATEK INC (301611.SZ)
- Rubis SCA (RUI.PA)
- All Winner Technology Co Ltd (300458.SZ)
- Neway Valve suzhou Co Ltd (603699.SS)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.